The release of these ligands subsequently activates EGFR and triggers both the mitogen-activated protein kinase (MAPK)/PI3K and Akt pathway in cancer cells, leading to increased proliferation and angiogenesis [67, 119, 120]. Here, EGFR is linked to cancer.